Shots:

• Chugai will receive an upfront- development milestone and royalties if the compound is launch as an approved Ab drug. Additionally- Chugai will receive a fee for technology access
• Novo Nordisk to get the rights to use several Chugai Ab engineering technologies for their research activities and optional right for the development and marketing of therapeutic Abs
• Novo Nordisk will utilize Chugai’s Ab engineering technologies targeting the unmet medical needs and create novel medicines

 ­ Ref: Chugai | Image: Peter Boyle Solicitors